Jack Saladow, vice president of marketing and sales at Ivera, said: “The licensing agreement between Becton, Dickinson and Company (BD) and Ivera broadens our existing patent applications and removes potential patent issues so we can move forward with the worldwide marketing and sales of the Curos Port Protector.”
Bob Rogers, CEO of Ivera Medical, said: “This license agreement between our two companies confirms our mutual commitment to assist healthcare providers in their efforts to reduce bloodstream infections. We believe a significant number of these infections are caused by touch or airborne contamination of needleless I.V. ports.”